Publications by authors named "Chad Reichard"

Claim this Profile
G
Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort.
Chad A Reichard, Bryan D Naelitz, Zeneng Wang, Xun Jia, Jianbo Li

Cancer Epidemiol Biomarkers Prev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.
Oluchi Oke, Weranja Ranasinghe, Chad Tang, Sherif Shaaban, Lianchun Xiao, Chad A Reichard

Eur Urol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Lamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, Debasish Sundi, Weranja Ranasinghe

Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urolithiasis in complicated inflammatory bowel disease: a comprehensive analysis of urine profile and stone composition.
Fabio C Torricelli, Chad Reichard, Manoj Monga

Int Urol Nephrol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
Weranja Ranasinghe, Daniel D Shapiro, Hyunsoo Hwang, Xuemei Wang, Chad A Reichard

Eur Urol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design.
Chad A Reichard, Janet Kukreja, Justin R Gregg, Tharakeswala K Bathala, Mary F Achim

Eur Urol Focus· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
Weranja Ranasinghe, Chad A Reichard, Yaw A Nyame, Debasish Sundi, Jeffrey J Tosoian

J Urol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort.
Justin R Gregg, John W Davis, Chad Reichard, Xuemei Wang, Mary Achim

Urology· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Jason W D Hearn, Christopher J Sweeney, Nima Almassi, Chad A Reichard, Chandana A Reddy

JAMA Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of cT4 Prostate Cancer.
Weranja K B Ranasinghe, Chad A Reichard, Tharakeswara Bathala, Brian F Chapin

Eur Urol Focus· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer.
Janet Baack Kukreja, Tharakeswara K Bathala, Chad A Reichard, Patricia Troncoso, Scott Delacroix

Prostate Cancer Prostatic Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical prostatectomy or radiotherapy for high- and very high-risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment.
Chad A Reichard, Karen E Hoffman, Chad Tang, Stephen B Williams, Pamela K Allen

BJU Int· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Weranja K B Ranasinghe, Chad A Reichard, Brian F Chapin

Eur Urol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial Comment.
Chad A Reichard, Brian F Chapin

Urology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?
Chad A Reichard, Yaw A Nyame, Debasish Sundi, Jeffrey Tosoian, Lamont Wilkins

BJU Int· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma.
Jonathan J Duplisea, Ross J Mason, Chad A Reichard, Roger Li, Yu Shen

Can Urol Assoc J· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance.
Justin R Gregg, David S Lopez, Chad Reichard, Jiali Zheng, Wenhui Wu

J Urol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
Debasish Sundi, Jeffrey J Tosoian, Yaw A Nyame, Ridwan Alam, Mary Achim, Chad A Reichard

Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance.
Justin R Gregg, Jiali Zheng, David S Lopez, Chad Reichard, Gladys Browman

Br J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging role of cytoreductive prostatectomy in patients with metastatic disease.
Yasmeen Jaber, Chad A Reichard, Brian F Chapin

Transl Androl Urol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes.
Chad A Reichard, Justin R Gregg, Mary F Achim, Ana M Aparicio, Curtis A Pettaway

Eur Urol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Nima Almassi, Chad Reichard, Jianbo Li, Carly Russell, Jaselle Perry

JAMA Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
Jason W D Hearn, Wanling Xie, Mari Nakabayashi, Nima Almassi, Chad A Reichard

JAMA Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Chad Reichard

J Urol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy.
Chad Reichard, Brian Francis Chapin

Eur Urol Focus· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis